1 Short title: Snotwatch COVID-toes: An ecological study

Long title: Snotwatch COVID-Toes: An ecological study of chilblains and COVID-19 diagnoses in Victoria, Australia

4 Authors:

- 5 Rana Sawires, BMedSci (Hons)^{1,2*}, Christopher Pearce, PhD⁷, Michael Fahey, PhD^{3,4}, Hazel
- 6 Clothier^{2,6} PhD, Karina Gardner, MCliEpi⁷, Jim Buttery, M.D.^{1,2,6}
- 7 ¹Department of Paediatrics, Faculty of Medicine, Nursing and Health Sciences, Monash
- 8 University, Victoria, Australia.
- 9 ²Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria,
- 10 Australia.
- ³Department of Neurology, Monash Children's Hospital, Victoria, Australia.
- 12 ⁴Neurogenetics Department, Monash Paediatrics, Monash University, Victoria, Australia.
- 13 ⁵School of Population & Global health, University of Melbourne, Victoria, Australia.
- 14 ⁶Child Health Informatics, Department of Paediatrics, University of Melbourne, Victoria,
- 15 Australia.
- 16 ⁷Outcome Health
- 17 * Corresponding Author: Rana Sawires
- 18 Email: rana.sawires@monash.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

20 Background

- 21 The COVID-19 pandemic has caused widespread illness with varying clinical manifestations.
- 22 One less-commonly-reported presentation of COVID-19 infection is chilblain-like lesions.
- 23 Aims
- 24 We conducted an ecological analysis of chilblain presentations in comparison with
- 25 confirmed and suspected COVID-19 infections in a primary care setting to establish that a
- 26 relationship exists between the two.

27 Study Design

- 28 Our study collated data from three Primary Health Networks across Victoria, Australia, from
- 29 2017-2021, to understand patterns of chilblain presentations prior to and throughout the
- 30 pandemic. Using a zero-inflated negative binomial regression analysis, we estimated the
- 31 relationship between local minimum temperature, COVID-19 infections and the frequency
- 32 of chilblain presentations.

33 Results

- 34 We found a 5.72 risk ratio of chilblain incidence in relation to COVID-19 infections and a
- 35 3.23 risk ratio associated with suspected COVID-19 infections. COVID-19 infections were
- 36 also more strongly associated with chilblain presentations in 0-16-year-olds throughout the
- 37 pandemic in Victoria.

38 Conclusion

- 39 Our study statistically demonstrates that chilblains are significantly associated with COVID-
- 40 19 infections in a primary care setting. This has major implications for clinicians aiming to
- 41 diagnose COVID-19 infections or determine the cause of a presentation of chilblains.

- 42 Additionally, we demonstrate the utility of large-scale primary care data and its potential
- 43 application to monitoring the spread of COVID-19 infections across the state, supporting
- 44 current epidemiological efforts for COVID-19 tracking.

45 Introduction

46	The global coronavirus disease-19 (COVID-19) pandemic caused widespread illness and
47	global economic disruption. In addition to the more common respiratory symptoms,
48	cutaneous manifestations were reported in some patients with COVID-19 ^{1, 2} particularly
49	chilblain-like skin changes. ³⁻⁵ Chilblains are an inflammatory dermatological condition
50	affecting the acral regions of the body, often affecting women and middle-aged adults. ⁶
51	They present more frequently in wet-weather seasons, such as late winter and early spring 6
52	and are caused by abnormal vasospasm in response to cold associated with an inflammatory
53	infiltrate composed of T cells, B cells and macrophages. ⁶ Until COVID-19, infectious causes
54	were not thought to be an association. ⁷
55	Finding a strong link between COVID-19 and chilblains has proven elusive. While an
56	international register of people with skin eruptions revealed 45% of 505 patients had
57	respiratory symptoms consistent with COVID-19, ⁸ other studies found no serological
58	evidence of COVID-19 infection in people with chilblains. ⁹ Given the difficulty synthesising
59	these contradictory findings, we aimed to establish and quantify the temporal relationship
60	of chilblains with COVID-19 in Victoria, Australia in an ecological framework. Using such a
61	large dataset lays the groundwork for future research and has substantial public health and
62	epidemiological implications for tracking COVID-19 viral spread in the community.

63 Methods

64 Data Collection

Data were extracted using the POLAR (POpulation Level Analysis and Reporting) analytics
 program developed by Outcome Health. The POLAR system collects and processes data

67	from constituent practices across Primary Health Networks (PHNs). PHNs contributing to
68	this study are located in Eastern Victoria (Eastern Melbourne, Gippsland and South-Eastern
69	Melbourne) representing 537 general practices with a pooled catchment of 3.65 million
70	patients (Figure 1). POLAR is an end-to-end analytics platform that collects and processes
71	electronic medical record information from general practices on behalf of PHNs. POLAR is
72	both a patient-level clinical decision support tool and a population health analytics platform.
73	Practices contributing data via the POLAR platform can engage in research activity by
74	agreeing to share de-identified snapshots of their data for ethics-reviewed, PHN-approved
75	research. Data collected by the POLAR system and shared for research is processed,
76	mapped, coded (to SNOMED codes), curated and redacted according to POLAR's Data De-
77	identification Decision-Making Framework (developed with guidance from the Office of the
78	Australian Information Commissioner). This yields a longitudinal dataset stripped of
79	identifiable information.
80	

Figure 1: Data was obtained from three Primary Health Networks, servicing 3.65 million
people in Victoria, Australia 2017-2021 (blue). Image adapted from Australian Government
Department of Health.¹⁰

84

85 Study design and cohort

Using data collected from participating General Practices (GPs) on behalf of PHNs, we
conducted a retrospective ecologic cohort analysis from January 2017- September 2021.
Inclusion criteria were any diagnoses of chilblains, COVID-19 disorder, or suspected COVID19 disorder recorded in any Victorian general practice located in one of the three

90	participating PHNs. SNOMED codes ¹¹ are an organised set of medical terms which provide
91	codes, synonyms and definitions for terms used in clinical documentation and reporting and
92	are used for organising data collected by POLAR. Our study cohort was generated using
93	SNOMED codes for conditions of interest: chilblains (SNOMED code 37869000), COVID-19
94	disorder (SNOMED code 840539006), and suspected COVID-19 (SNOMED code 840544004).
95	Data extracted included: the patient's age in years and the date of diagnosis. Data were de-
96	identified. COVID-19 disorder is a code used for patients who have had a positive
97	polymerase chain reaction (PCR) test for COVID-19 infection and recorded in the GP
98	software. Suspected COVID-19 codes are used for symptomatic patients who have not had a
99	positive PCR test for COVID-19 infection.
100	Additionally, we obtained local daily minimum temperature data from all weather stations
101	in Victoria from the Bureau of Meteorology (BOM) from January 2017- September 2021 and
102	aggregated these data across the state. This yielded average statewide minimum
103	temperature data.
104	All data were then aggregated by the week of the year, where the weeks were calculated
105	from Monday to Sunday. The first and last weeks of the year were included independently
106	regardless of the day of the week they started or ended, respectively.
107	Statistical Analysis
108	The coding program, R (version 4.0.2), ¹² was applied through RStudio (version 1.2.5) ¹³ for
109	statistical analysis of temporal data. Following fit testing of the distribution of our data, we

- 110 determined that conducting a zero-inflated negative binomial regression analysis would be
- 111 the most suitable technique for modelling our data. We created a multivariate model, which
- used weekly minimum temperature, COVID-19 and suspected COVID-19 diagnoses to

- 113 predict chilblains. To meaningfully determine the effect of temperature on chilblains, we
- 114 used a negative transformation of the temperature data.
- 115 Additionally, to assess the possible lag in any association between chilblains and the COVID-
- 116 19 diagnoses, we created lead and lag models for our datasets, eight exploring leads in
- 117 chilblains diagnoses, and eight exploring lags. We assessed the relationship between COVID-
- 118 19 and chilblains in different age groups (0-16 years, 17-49 years, and 50 years and over). To
- assess the effect of COVID-19 diagnoses on chilblains presentations we compared the risk of
- 120 chilblains when COVID-19 diagnoses were present at or above the 95th percentile of their
- 121 maximum rate to the 50th centile of their maximum rate. Our significance level was set at
- 122 p<0.01.

123 Ethics approval

- 124 Ethical approval for Snotwatch projects was obtained through our primary Human Research
- 125 Ethics Committee (HREC) in Monash Health from 24th July 2019 (NMA/ERM Reference

126 Number: 53611).

- 127 For the use of data from POLAR GP, additional approval was obtained under Monash Health
- 128 (Monash Health Reference Number: RES-18-0000-232A, NMA HREC Reference Number:

129 HREC/18/MonH/345).

- 130 The extraction, storage and management of data on the POLAR platform has ethics approval
- 131 from the RACGP National Research and Evaluation Research Committee (Protocol ID: 17-
- 132 008). Ethics approval for this project was granted by the Monash Health Human Research
- 133 Ethics Committee (Ref No: 21-013L).

134 Results

135 Cohort Demographics

- 136 From January 2017-September 2021, there were a total of 6,846 chilblains diagnoses across
- the three participating PHNs in Victoria. The distribution of chilblains across the age groups
- approximately matched that of the Victorian population.
- 139 A total of 3,687 diagnoses of COVID-19 disorders and 4,688 diagnoses of suspected COVID-
- 140 19 were recorded in a GP setting from January 2020- September 2021. We excluded four
- 141 diagnoses of COVID-19 disorder and one diagnosis of suspected COVID-19 disorder that
- 142 occurred before January 2020 as these were assumed to be errors in the system. These
- 143 exclusions are unlikely to alter the findings of our study.
- 144 Bureau of Meteorology Temperature Data
- 145 Victoria is a region with a moderate climate in the Southern Hemisphere. We obtained
- 146 aggregated BOM for minimum temperature across the state of Victoria. The median
- 147 minimum temperature for Victoria was 8.12 degrees Celsius (Interquartile Range 5.53-
- 148 12.08). The minimum and maximum temperatures for each year remained consistent, with
- only a slightly lower maximum temperature in 2021, which is likely because the data ended
- 150 in September, prior to the beginning of the 2021 summer season.

151 Data Visualisation

- 152 A clear peak of chilblains presentations was evident in winter of each year. This coincided
- 153 with decreasing temperature throughout the 5-year period. COVID-19 disorder, and
- 154 suspected COVID-19 disorder mirrored the peak in chilblains in 2020 very closely but lagged
- the chilblains peak in 2021. (Figure 2)

156

157 Figure 2: Weekly number of chilblains diagnoses, COVID-19 diagnoses and Minimum

- 158 *Temperature in Victoria 2017-2021*
- 159
- 160 Associations of chilblains with COVID-19 diagnoses and average minimum
- 161 temperature
- 162 In Victoria, chilblains were significantly associated with a reduction in temperature, having a
- risk ratio (RR) of 1.33 (99%Cl 1.27-1.40) per 1°Celcius. When comparing the 95th centile to
- 164 50th centile of COVID-19 and suspected COVID-19 diagnoses, there was a 5.72 RR (99%CI
- 165 2.27-14.44) and 3.23 RR (99%CI 1.32-7.91) of chilblains presentations respectively. Lead and
- 166 lag analyses did not demonstrate any meaningful temporal associations between chilblains
- and COVID-19 in a general practice setting. The complete table is shown in S1 Appendix A.
- 168 Both COVID-19 diagnosis and suspected COVID-19 also had a greater association with
- 169 chilblains in 0-16-year-old children with chilblains (5.96 RR and 4.34 RR respectively). The
- size of the association reduced with each age group, with only a 3.03 RR and 1.69 RR
- 171 respectively with chilblains in people 50 years and over. The results from our subgroup
- 172 analyses are shown in Table 1.
- 173

Table 1: Associations between COVID-19 disorder, suspected COVID-19 disorder and
decreasing temperature with chilblains in different age groups. All results were statistically
significant.

	RR OF	RR OF	RR OF	RR OF
	CHILBLAINS	CHILBLAINS	CHILBLAINS	CHILBLAINS
	ALL COHORT	IN 0-16-YEAR-	IN 17-49-	IN 50 YEARS
	(99% CI)	OLDS (99% CI)	YEAR-OLDS	AND OVER
			(99% CI)	(99% CI)
COVID-19	5.72 (2.27-14.44)	5.96 (1.68-21.18)	4.98 (2.00-12.38)	3.03 (1.42-6.46)
DISORDER				
SUSPECTED	3.23 (1.32-7.91)	4.34 (1.31-14.32)	3.59 (1.49-8.68)	1.69 (0.84-3.40)
COVID-19				
DECREASING	1.33 (1.27-1.40)	1.27 (1.15-1.41)	1.32 (1.24-1.40)	1.29 (1.23-1.36)
TEMPERATURE				
(PER 1°C)				

177

178 Discussion

179	To our knowledge, this is the largest population-level ecological study of the relationship
180	between COVID-19 and presentations of chilblains in a GP setting. We found increases in
181	diagnoses of chilblains in participating PHNs that could be significantly correlated with
182	COVID-19 circulation in Victoria. Our study confirms findings in most of the existing
183	literature. Since the beginning of 2020, chilblains have been reported in conjunction with
184	COVID-19 disorder in several European case series and one epidemiological study in
185	California. ^{3, 4, 14} Nevertheless, it is still uncertain whether COVID-19 infection is the cause of
186	these presentations. While in some cases, a causal relationship has been supported by
187	positive PCR results ^{4, 15} or serology, ¹⁶ the vast majority of studies show a low rate of PCR
188	positivity for COVID-19 diagnoses in patients who present with chilblains. ^{17, 18}

189 The mechanism of chilblains presentations in COVID-19 infectious is unknown. One

- 190 systematic review showed that the cutaneous manifestations of COVID-19 infection could
- 191 be due to increased ACE2 expressions in the skin, although the specific method of erythema
- 192 development in COVID-19 infection remains unclear.¹⁹
- 193 Additionally, there is uncertainty surrounding the diagnosis of cutaneous manifestations of
- 194 COVID-19 infections. Histological confirmation of chilblains diagnosis requires a skin biopsy
- 195 that demonstrates a superficial and deep lymphocytic inflammatory infiltrate in a lichenoid,
- 196 perivascular, and peri-eccrine distribution.²⁰ However, there is no consensus on whether
- 197 chilblains in the context of COVID-19 infections have the same histological features as
- 198 idiopathic chilblains.¹⁶
- 199 In light of the difficulty in delineating the pathophysiological association between COVID-19
- 200 infection and chilblains, it has been suggested that behaviour changes during lockdowns,
- such as not wearing shoes or socks in the home, leaving extremities more exposed to the
- 202 cold, could explain the possible increase in the number of chilblains presentations over the
- 203 course of the pandemic.²¹ One explanation is that in response to COVID-19 infection, a high
- 204 level of type I interferons (IFN) (as seen in familial chilblains lupus) could itself be the cause
- for the development of chilblains.²² Further research is required to ascertain whether this is
 the case.
- 207 Our findings showed that COVID-19 disorder diagnoses were most strongly associated with 208 chilblains presentations in the same week, whereas suspected COVID-19 disorder was 209 associated with chilblains presentations in the preceding and following weeks more 210 strongly.

Studies have suggested that various cutaneous manifestations of COVID-19 can precede, lag
or coincide with extracutaneous symptoms of COVID-19 infection or a confirmed COVID-19
diagnosis.² More specifically, chilblain-like lesions are the latest to present, with a 2-8-week

- 214 lag following respiratory COVID-19 symptoms.^{5, 16}
- 215 Chilblains may also be a late manifestation of the disease and PCR testing could yield
- negative by the time of assessment due to a reduced viral load.¹ A survey of eight paediatric
- 217 patients showed an average of 19.6 days delay between chilblains symptom onset and
- visiting a dermatology clinic,¹³ and a case series spanning 8 countries, showed that chilblains
- 219 lasted a median of 14 days.⁸ By contrast, it has been reported that in subgroups of patients
- 220 with COVID-19-associated-chilblains, PCR results were positive at day 8 of testing but
- 221 became negative by day 14.²³ Thus, these factors could explain the low rates of positive PCR
- findings demonstrated in a number of studies.^{4, 15}

223 Despite this, our study still showed an association between confirmed COVID-19 cases and 224 chilblains in the same week, and no statistically significant associations were found when 225 delays between chilblains and COVID-19 disorder was analysed. This could be explained by 226 the widespread use of telehealth during the pandemic which would have meant that 227 chilblains diagnoses temporally coincided with COVID-19 infections.²⁴ Nevertheless, time 228 delays in association with suspected COVID were found and further investigation is needed 229 to ascertain whether COVID-19 infection plays a role in the development of chilblains.

- 230 In addition to a high proportion of chilblains in our paediatric age group (18.7%), a key
- 231 finding of our study was that the association of COVID-19 infection was greatest with
- chilblains presentations in 0–16-year-old children. Consistent with our study, chilblain-like
- 233 lesions in the context of COVID-19 disease have been more commonly reported in teenagers

and young adults.^{1, 2, 8, 21} Paediatric patients with chilblains often lack respiratory 234 235 symptoms¹⁴ and have a low rate of positive PCR for COVID-19 infection.^{16, 25} It has been 236 proposed that children and young adults have a more robust innate immune response leading to reduced viral load and negative PCR tests.^{20, 21} These findings stand in contrast to 237 238 idiopathic chilblains which are historically more common in middle-aged people⁷ and very 239 rarely reported in children.²⁶ This may imply that chilblain-like lesions in COVID-19 have a 240 different pathophysiology from idiopathic chilblains and requires further investigation. 241 The key advantage of our study compared to existing literature is that our ecological study design yields a significant sample size. This adds significant power to our analysis and the 242 243 findings of our study. This study design also enabled us to meaningfully analyse whether 244 leads and lags existed between the timing of our diagnoses. Decreasing temperature is a key 245 cause of chilblains presentations and our study accounted for this by including these data in 246 our analysis. This means that the increase in chilblains presentations in 2020 and 2021 could 247 be more reliably associated with COVID-19. Additionally, the low p-value for significance in our study gives greater confidence in the strength of our associations. 248 249 Nevertheless, there are some key limitations to our dataset. Over the course of the 250 pandemic, most COVID-19 diagnoses in Victoria were not made in a GP setting. As such, our 251 chilblains diagnosis data are only a subset of all COVID-19 infections that occurred in the last 252 two years. There is also uncertainty around how general practitioners coded COVID-19 253 diagnoses and whether there was a time delay between a patient having a confirmed 254 COVID-19 infection and their general practice visit at which this diagnosis would have been 255 recorded. We included suspected COVID-19 diagnosis in our analysis for completion, but this 256 is an unreliable measure of COVID-19 infection in the state and may not accurately

257 represent circulation of COVID-19 infections in Victoria. An additional factor to consider is

- 258 that a significant proportion of cases in Victoria were diagnosed through state-run testing
- 259 hubs with minimal notification back to GPs. This may have skewed our results and masked
- 260 possible lead and lag associations between chilblains and COVID-19.
- 261 Ultimately, the ecological analysis conducted in this study means that we can only
- 262 demonstrate associations between our datasets, and a causal relationship between COVID-
- 263 19 infection and chilblains presentations cannot be confirmed. Nevertheless, our findings
- lay the foundation for future research which may confirm a causal relationship, as well as
- ascertain the pathophysiology and aetiology of chilblains due to COVID-19 infection.

266 Conclusion

- 267 Our Victorian ecological study of chilblains and COVID-19 showed a significant association
- 268 between these presentations in Victorian general practices during the first two years of the
- 269 COVID-19 pandemic. Using novel statistical methodology, our study can inform
- 270 epidemiological understanding of COVID-19 circulation in a given region and population.
- 271 Additionally, existing research to ascertain the causal relationship between the novel
- 272 coronavirus and chilblains is scant. However, the size of association found in our study
- 273 demonstrates that further investigation is warranted.
- 274 Finally, these findings have significant implications for the potential use of large-scale
- 275 primary care data for monitoring the circulation of COVID-19, using chilblains presentations
- as a surrogate measure for the spread of COVID-19 infections.

277	Bibliography:	
278		
279	1. Galvan Casas C, Catala A, Carretero Hernandez G, Rodriguez-Jimenez P, Fernandez-	-
280	Nieto D, Rodriguez-Villa Lario A, et al. Classification of the cutaneous manifestations of	
281	COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J	
282	Dermatol. 2020;183(1):71-7.	
283	2. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An	
284	Evidence-Based Review. Am J Clin Dermatol. 2020;21(5):627-39.	
285	3. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on	
286	feet and hands during the COVID-19 Pandemic. Int J Dermatol. 2020;59(6):739-43.	
287	4. McCleskey PE, Zimmerman B, Lieberman A, Liu L, Chen C, Gorouhi F, et al.	
288	Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic.	
289	JAMA Dermatol. 2021;157(8):947-53.	
290	5. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-Like Lesions (CLL) Associated Wit	th
291	COVID-19 ("COVID Toes"): A Systematic Review. J Cutan Med Surg.	
292	2021:12034754211004575.	
293	6. Nyssen A, Benhadou F, Magnee M, Andre J, Koopmansch C, Wautrecht JC. Chilblair	าร.
294	Vasa. 2020;49(2):133-40.	
295	7. Cappel JA, Wetter DA. Clinical characteristics, etiologic associations, laboratory	
296	findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of	
297	104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc. 2014;89(2):207-15.	

- 298 8. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al.
- 299 Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8
- 300 countries. J Am Acad Dermatol. 2020;83(2):486-92.
- 301 9. Balestri R, Magnano M, Rizzoli L, Rech G. Do we have serological evidences that
- 302 chilblain-like lesions are related to SARS-CoV-2? A review of the literature. Dermatol Ther.
- 303 2020;33(6):e14229.
- 304 10. Department of Health. Victoria PHNs boundaries across the state. Canberra:
- 305 Department of Health; April 2018. Available from:
- 306 <u>https://www.health.gov.au/resources/publications/victoria-primary-health-networks-phn-</u>
- 307 <u>boundary-maps</u>
- 308 11. Organisation IHTSD. SNOMED International: International Health Terminology
- 309 Standards Development Organisation 2021. Available from: https://www.snomed.org/
- 310 12. R Development Core Team. R: A language and environment for statistical computing.
- 311 Vienna, Austria: R Foundation for Statistical Computing; 2010.
- 312 13. RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA
- 313 2015.
- 314 14. Garcia-Lara G, Linares-Gonzalez L, Rodenas-Herranz T, Ruiz-Villaverde R. Chilblain-
- 315 like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak.
- 316 Dermatol Ther. 2020;33(5):e13516.
- 317 15. Recalcati S, Fantini F. Chilblain-like lesions during the COVID-19 pandemic: early or
- 318 late sign? Int J Dermatol. 2020;59(8):e268-e9.
- 16. El Hachem M, Diociaiuti A, Concato C, Carsetti R, Carnevale C, Ciofi Degli Atti M, et al.
- A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric

- 321 patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19
- 322 infection. J Eur Acad Dermatol Venereol. 2020;34(11):2620-9.
- 323 17. Gisondi P, S PI, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations
- of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34(11):2499-
- 325 504.
- 326 18. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-
- 327 like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad
- 328 Dermatol Venereol. 2020;34(7):e291-e3.
- 329 19. Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous
- manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(11):2505-10.
- 331 20. Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes
- 332 Unified Through Cutaneous and Systemic Mechanisms. Mayo Clin Proc. 2021;96(4):989-
- 333 1005.
- 334 21. Neri I, Virdi A, Corsini I, Guglielmo A, Lazzarotto T, Gabrielli L, et al. Major cluster of
- 335 paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of
- lifestyle changes due to lockdown. J Eur Acad Dermatol Venereol. 2020;34(11):2630-5.
- 337 22. Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-
- 338 like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad
- 339 Dermatol. 2020;83(3):e269-e70.
- 340 23. Freeman EE, McMahon DE, Hruza GJ, Lipoff JB, French LE, Fox LP, et al. Timing of PCR
 341 and antibody testing in patients with COVID-19-associated dermatologic manifestations. J
 342 Am Acad Dermatol. 2021;84(2):505-7.

343	24.	Snoswell CL, Caffery LJ, Haydon HM, Thomas EE, Smith AC. Telehealth uptake in	
344	genera	l practice as a result of the coronavirus (COVID-19) pandemic. Aust Health Rev.	
345	2020;44(5):737-40.		
346	25.	Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al.	
347	Clinica	l, Laboratory, and Interferon-Alpha Response Characteristics of Patients With	
348	Chilbla	in-like Lesions During the COVID-19 Pandemic. JAMA Dermatol. 2021;157(2):202-6.	
349	26.	Simon TD, Soep JB, Hollister JR. Pernio in pediatrics. Pediatrics. 2005;116(3):e472-5.	
350			

- 352 S1:
- 353 Appendix A: Chilblains, COVID-19 disorder and Suspected COVID-19 disorder lead and
- **354** lag analysis results
- 355 Table 2: COVID-19, Suspected COVID-19 and Temperature associations with Chilblains with
- 356 *leads and lags*
- 357



Figure 1

Chilblains, COVID-19 and Minimum Temperature 2017-2021

Chilblains 🝝 COVID-19 Disorder 🔸 Suspected COVID-19 Disorder 🔹 Min Temperature (degC)



Figure 2